Tredje AP fonden Buys 506 Shares of United Therapeutics Corporation $UTHR

Tredje AP fonden boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 10.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,186 shares of the biotechnology company’s stock after purchasing an additional 506 shares during the period. Tredje AP fonden’s holdings in United Therapeutics were worth $1,490,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Triglav Investments D.O.O. purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $1,149,000. Great Lakes Retirement Inc. lifted its stake in shares of United Therapeutics by 7.4% in the 2nd quarter. Great Lakes Retirement Inc. now owns 4,310 shares of the biotechnology company’s stock valued at $1,238,000 after purchasing an additional 296 shares during the period. Virtus Family Office LLC bought a new position in United Therapeutics in the second quarter worth $1,161,000. Atria Investments Inc raised its holdings in United Therapeutics by 12.6% in the second quarter. Atria Investments Inc now owns 945 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 106 shares in the last quarter. Finally, Retirement Systems of Alabama lifted its position in United Therapeutics by 0.7% during the 2nd quarter. Retirement Systems of Alabama now owns 118,982 shares of the biotechnology company’s stock valued at $34,189,000 after acquiring an additional 794 shares during the period. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 368,435 shares of company stock worth $152,863,012. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Trading Down 1.8%

United Therapeutics stock opened at $445.43 on Monday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $479.50. The firm has a market capitalization of $19.18 billion, a price-to-earnings ratio of 16.88, a P/E/G ratio of 4.96 and a beta of 0.66. The firm has a 50 day moving average of $410.07 and a 200 day moving average of $338.73.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the business posted $6.39 earnings per share. On average, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Wednesday. HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Finally, Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $501.90.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.